Supriya Lifescience shares dropped 12% on Monday following news that a senior executive was placed in judicial custody. The Customs Department initiated action regarding a procedural lapse in an export transaction. The company stated the incident is not expected to materially affect its operations or financial position.
Supriya Lifescience saw its share price fall by 12% in intra-day trading on Monday, reaching ₹863.50 on the BSE. This decline follows a company disclosure regarding judicial proceedings against Sreekant Sreedharan, the General Manager of Sales and Marketing.
The Special Investigation and Intelligence branch of the Customs Department initiated the action on July 3, 2026, under the Narcotic Drugs and Psychotropic Substances Act. According to the company, the case relates to a procedural lapse involving a single export transaction. The Chief Metropolitan Magistrate court has granted judicial custody to the executive until July 17, 2026.
Impact and Company Response
Investors are reacting to the legal uncertainty surrounding a senior member of the company's sales team. In its exchange filing, Supriya Lifescience stated that it does not expect these proceedings to have a material impact on its operations, financial health, or governance standards. The company is currently seeking legal counsel to address the matter and has pledged to keep shareholders informed of any further developments.
This stock price movement follows a period of high volatility for the company, which saw a 14% decline earlier on June 2, 2026. For context, the stock has traded within a 52-week range of ₹545.65 on March 24, 2026, and a peak of ₹1,085.50 on June 1, 2026.
Business Context and Outlook
Despite the immediate market reaction to the legal news, analysts at Choice Institutional Equities continue to maintain a positive view on the company’s business fundamentals. The firm projects strong year-on-year revenue growth for the June 2026 quarter, largely aided by a low base from the previous year. However, investors may note that the company is currently incurring costs related to the scale-up of new facilities, which may lead to a temporary contraction in profit margins in the near term.
Moving forward, the company's financial performance will likely depend on its progress in specific business areas. Key items to track include updates on its Good Laboratory Practice certifications, the status of its Contract Development and Manufacturing Organisation (CDMO) contracts, and the successful launch of new Active Pharmaceutical Ingredient (API) molecules. Long-term expectations for margin improvement remain tied to the company's focus on niche therapies and its internal production capabilities, though these will be balanced against the need for consistent regulatory compliance.